

Celgene Corporation Investor Relations Department 86 Morris Avenue Summit, NJ 07901 United States

Visit IR website ☐ Sign-up for e-mail alerts ☐

NASDAQ: CELG	
Last Trade:	122.37
Trade Time:	4:00 PM ET Oct 23, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	96.93 - 147.17
Volume	110

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immuneinflammatory related diseases. Our portfolio of commercial products include REVLIMID®. VIDAZA[®], THALOMID[®], POMALYST®/IMNOVID®. ABRAXANE®, OTEZLA®, ISTODAX® and IDHIFA®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... (more)

Stock Performance



Press Releases [View all]

Oct 19, 2017

<u>Celgene Provides Update on GED-0301</u> (mongersen) Inflammatory Bowel Disease <u>Program</u>

Oct 19, 2017

Phase III Efficacy and Safety Data for Oral
Ozanimod in Relapsing Multiple Sclerosis to
Be Presented at MSParis2017 - 7th Joint
ECTRIMS - ACTRIMS Meeting

Oct 16, 2017

Results from Phase 2 Studies of Oral

Ozanimod in Crohn's Disease and Ulcerative

Colitis to Be Presented at World Congress of

Gastroenterology at ACG2017

Oct 2, 2017

Celgene Corporation to Announce Third
Quarter 2017 Results on October 26, 2017;
Will Host an Investor Webcast Event from
the MSParis2017-7th Joint ECTRIMS ACTRIMS Meeting on October 28, 2017

Sep 8, 2017

Data Presented at ESMO 2017 Further

Evaluate Role of ABRAXANE® for Patients
with Historically Challenging Cancers

Upcoming Events [View all]

Oct 26, 2017 9:00 AM ET

<u>Celgene Corporation Q3 2017 Celgene Corp.</u> Earnings Conference Call

Oct 28, 2017 12:00 PM ET Celgene Event at ECTRIMS

Financials [View all]

Feb 10, 2017 Annual Report (10-K)

Apr 27, 2017
Proxy Statement (DEF 14A)

Jul 27, 2017

Quarterly Report (10-Q)

Apr 27, 2017

Quarterly Report (10-Q)

Oct 27, 2016

Quarterly Report (10-Q)